Winst gevend schreef op 3 november 2021 23:12:
Takeda: afdeling Takhzyro HAE prophylaxe.
Rare Diseases with 300.1 billion yen ($2.69B) in reported revenue declined -2% on an underlying basis
with rare hematology decline in line with expectations due to competition and
HAE growth
being impacted by phasing dynamics; remain on track toward full year forecast.
2.69 miljard Dollar verlies door een sterke omzetdaling in HAE.
Hoe kan BioCryst dan maar $37 miljoen omzet hebben met een netto verlies van $58 miljoen?